Burgmann H
Innere Medizin I, Klinische Abteilung für Infektionen und Tropenmedizin, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich,
Med Klin Intensivmed Notfmed. 2014 Nov;109(8):577-82. doi: 10.1007/s00063-014-0378-8. Epub 2014 Oct 26.
The Surviving Sepsis Campaign strongly recommends that intravenous antibiotic therapy should be started as early as possible, ideally within the first hour of recognition of severe sepsis or septic shock. There is ample evidence that failure to initiate early antimicrobial treatment correlates with increased morbidity and mortality.
The purpose of this work was to review the recent literature regarding optimal initial antimicrobial treatment in patients with severe sepsis and sepsis shock.
A literature review was performed.
The most frequently quoted papers claiming the overriding prognostic importance of early administered antibiotics are retrospective data analyses. However, an equivalent number of studies report that a group of septic patients do not benefit from early administration of antibiotics, but can also be harmed. In these patients, watchful waiting with administration of a targeted antibiotic can be used, thus, avoiding the possible collateral damage from excessive treatment with antibiotics. Treatment with monotherapy is adequate in most cases.
The administration of antibiotics based on the local epidemiology should be initiated quickly in critically ill patients with severe sepsis and septic shock. In patients who are not in septic shock, treatment can be withheld, while awaiting further studies or clinical assessment to confirm the suspicion of infection.
拯救脓毒症运动强烈建议应尽早开始静脉抗生素治疗,理想情况是在识别出严重脓毒症或脓毒性休克后的第一小时内。有充分证据表明,未能尽早开始抗菌治疗与发病率和死亡率增加相关。
这项工作的目的是回顾近期关于严重脓毒症和脓毒性休克患者最佳初始抗菌治疗的文献。
进行了文献综述。
最常被引用的声称早期使用抗生素具有首要预后重要性的论文是回顾性数据分析。然而,同样数量的研究报告称,一组脓毒症患者并未从早期使用抗生素中获益,反而可能受到伤害。对于这些患者,可以采用观察等待并给予针对性抗生素的方法,从而避免过度使用抗生素可能带来的附带损害。大多数情况下,单一疗法就足够了。
对于患有严重脓毒症和脓毒性休克的危重症患者,应根据当地流行病学情况迅速开始使用抗生素。对于未发生脓毒性休克的患者,可以在等待进一步研究或临床评估以确认感染怀疑之前暂不进行治疗。